Auto-immune Diseases and Quality of Life

Qualitative Study of the Consequences of Auto-immune Diseases on Quality of Life

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02855840

Acronym

QUALIMAIRAU

Enrollment

Registered

2016-08-04

Start date

2015-03-02

Completion date

2017-03-31

Last updated

2017-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of Life, Systemic Auto-immune Diseases

Brief summary

Systemic lupus erythematous (SLE), systemic sclerosis (Ssc) and inflammatory myopathy (IM) are rare diseases, whose prevalence is estimated at 43, 15 and 10 cases, respectively, for 100 000 inhabitants in France. These diseases belong to the group of auto-immune diseases and require specialized follow-up in an expert centre. The repercussions of SLE, Ssc and IM on the everyday life of patients are heavy, and notably linked to skin involvement, to diminished functional capacities and psychological problems. The vast majority of these diseases concern middle-aged, professionally-active individuals, for whom the socio-professional repercussions are major and too often neglected. The aim of this study is to analyse the consequences of auto-immune diseases on quality of life. Current quality of life questionnaires are not suitable, and do not reveal the reality of the situation and its different nuances. In this research, the quality of life of patients will be envisaged through their everyday lives. How do these patients construct the social reality of the disease? How do they perceive their health status and their social situation? How do they organize their everyday lives around the disease: work, leisure, relationships with their entourage... ?

Interventions

OTHERcompletion of the quality of life questionnaire

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* For all patients: * Patients aged 18 to 75 years * Patients able to understand written and spoken French * Patients who have been given oral and written information about the research For patients with SLE: \- SLE defined by American College of Rheumatology (ACR) 1997 criteria For patients with systemic sclerosis: \- SSc according to the Leroy or American Rheumatism Association (ARA) criteria For patients with IM: \- IM according to the Trojanov criteria

Exclusion criteria

* Refusal to take part in the study * Cognitive/psychological status incompatible with interviews

Design outcomes

Primary

Measure	Time frame
semi-directive individual interviews in the 3 groups of patients	day one

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026